Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
C4 Therapeutics ( (CCCC) ) has provided an announcement.
On June 18, 2025, C4 Therapeutics held its Annual Meeting of Stockholders, where key decisions were made regarding the company’s governance and operational strategies. Stockholders elected three Class II directors, approved executive compensation, ratified KPMG LLP as the independent auditor, and agreed to amend the company’s certificate of incorporation to double the authorized shares of common stock, reflecting strategic growth ambitions.
The most recent analyst rating on (CCCC) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on C4 Therapeutics stock, see the CCCC Stock Forecast page.
Spark’s Take on CCCC Stock
According to Spark, TipRanks’ AI Analyst, CCCC is a Neutral.
The overall stock score reflects significant financial and valuation challenges, with persistent losses and negative cash flows. Despite stable balance sheet indicators, the lack of profitability and negative P/E ratio weigh heavily. Technical analysis offers some optimism with mixed signals, but the stock remains below key moving averages.
To see Spark’s full report on CCCC stock, click here.
More about C4 Therapeutics
C4 Therapeutics, Inc. operates in the biotechnology industry, focusing on the development of novel therapies for the treatment of cancer and other diseases. The company is known for its innovative approach to targeted protein degradation, aiming to provide new treatment options for patients with unmet medical needs.
Average Trading Volume: 1,098,089
Technical Sentiment Signal: Sell
Current Market Cap: $115.7M
For an in-depth examination of CCCC stock, go to TipRanks’ Overview page.